China's domestically produced new crown oral drugs passed the preliminary formal review of the adjustment of the 2022 medical insurance drug list
China News Service, Beijing, September 7 (Reporter Li Chun) The National Medical Security Administration of China recently announced the drugs and related information that have passed the preliminary formal review for the adjustment of the 2022 medical insurance drug list.
According to the list, a total of 344 drugs have passed the preliminary formal review, including the Chinese-made oral drug Azvudine Tablets for the new crown pneumonia that has been included in the diagnosis and treatment plan of the new crown pneumonia.
According to the 2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (National Medical Insurance Drug Catalog) to adjust the work arrangement, the National Medical Insurance Bureau recently conducted a preliminary formal review of the declared drugs.
Preliminary formal review is a preliminary review of whether the applied drug meets the application conditions for the adjustment of the National Medical Insurance Drug Catalogue and the completeness of drug information.
Passing the formal review does not mean being included in the National Medical Insurance Drug List. Follow-up procedures such as expert review, negotiation and bidding are required.
According to the National Medical Insurance Bureau, from 9:00 on July 1, 2022 to 17:00 on July 14, 2022, the National Medical Insurance Information Platform has received a total of 537 enterprise declaration information, involving 490 drugs.
After review, 344 drugs passed the preliminary formal examination, and the passing ratio was 70%.
Compared with 2021, the number of drugs submitted and passed preliminary formal examination has increased to a certain extent.
In terms of pass rate, the proportion of drugs outside the catalog is 60%, and the proportion of drugs in the catalog is 91%.
This includes Azvudine tablets.
The drug is an oral small-molecule novel coronavirus pneumonia treatment drug independently developed by China and has been included in China's novel coronavirus pneumonia diagnosis and treatment plan.
According to reports, the drug was officially put into production in Henan Province in early August this year.
The National Medical Insurance Administration stated that under the background of normalization of epidemic prevention and control, since the first implementation of the self-reporting system for medical insurance drug catalogue companies in 2020, the National Medical Insurance Administration has attached great importance to the treatment of new coronary pneumonia. "Drugs of the Virus Pneumonia Diagnosis and Treatment Program" as one of the application conditions.
A batch of new crown treatment drugs have been included in the list of medical insurance drugs.
This year, the ninth edition of China's new crown pneumonia diagnosis and treatment plan included a batch of drugs that have just been launched in China.
In the process of this application, some drugs have been self-reported and passed the preliminary formal review.
For the drugs that have been declared and passed the formal examination, the National Medical Insurance Bureau will carry out follow-up work according to the procedures, and strive to be officially included in the medical insurance catalog at a reasonable price.
Regarding how the work will be carried out after this announcement, the National Medical Insurance Administration said that the next step will be based on the feedback received during the announcement, to further verify the relevant information, determine the scope of drugs that have finally passed the formal review, and announce to the public.
Subsequently, the National Medical Insurance Administration will advance follow-up work such as expert review, negotiation and bidding as planned.
(Finish)